immune inhibition by HBV and circulating HBsAg

[stef2011]

http://publishing.eur.nl/ir/repub/asset/18503/100317_Op%20den%20Brouw,%20Marjoleine%20Louise.pdf

interesting at page 35

[stef2011]

Successful immunotherapy of chronic HBV patients should therefore aim first on reduction of viral load and viral antigens in order to restore the immune system and thereafter on boosting the immune system to clear the chronic infection.

so ntz decreased hbsag production and entecavir or tenofovir hbvdna reduction might be of great help before starting interferon which boosts immune function

without knowing about this research this is what we are doing with my therapy in pisa, the researcher wants to start interferon only when hbsag is lower than 1000-1500iu/ml since interferon has very high rates of seroconversion in this situation

[stef2011]

In conclusion, these results show that both HBV particles and purified HBsAg have an
immune modulatory capacity and may directly contribute to the dysfunction of mDC in chronic
HBV patients. The direct immune regulatory effect of HBV and circulating HBsAg particles on the function of DC can be considered as part of the mechanism by which HBV escapes immunity.
Successful immunotherapy of chronic HBV patients should therefore aim first on reduction of viral load and viral antigens in order to restore the immune system and thereafter on boosting the immune system to clear the chronic infection.